Stockscreener 앱 받기
48.04
2.89%
-1.43
시간 외 거래:
48.07
0.03
+0.06%
전일 마감가:
$49.47
열려 있는:
$49.5
하루 거래량:
405.38K
Relative Volume:
0.53
시가총액:
$3.41B
수익:
-
순이익/손실:
$-170.73M
주가수익비율:
-17.84
EPS:
-2.6921
순현금흐름:
$-159.70M
1주 성능:
-2.20%
1개월 성능:
-10.49%
6개월 성능:
-45.69%
1년 성능:
+169.89%
1일 변동 폭
$46.81
$49.50
1주일 범위
$46.40
$51.30
52주 변동 폭
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(650) 457-1978
주소
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
48.04 | 3.46B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Canaccord Genuity | Buy |
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC) - The Globe and Mail
GPCR|Structure Therapeutics Inc|Price:49.000| - TradingKey
Form 4 Structure Therapeutics Inc ADR For: 24 July By Investing.com - Investing.com South Africa
A small-cap contender looking to challenge the weight-loss drug giants | 2026-07-24 | Investing News - Stockhouse
FMR LLC Discloses Major Beneficial Ownership Changes in Structure Therapeutics Inc. - Kalkine Media
FMR LLC funds sell 17,452 Structure Therapeutics (GPCR) ADS at $50.07 - Stock Titan
GPCR: Structure Therapeutics IncADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results? - TradingView
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Does EU Approval of Wegovy Pill Change NVO's Competitive Story? - TradingView
(GPCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week - TechStock²
Takeover Buzz Sends Structure Therapeutics Soaring - TipRanks
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Fractyl Health, Inc. (GUTS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Merck & Company (MRK) and Viking Therapeutics (VKTX) - The Globe and Mail
Structure Therapeutics Slumps As Obesity Hype Cools - TipRanks
Form 4 Structure Therapeutics Inc ADR For: 15 July By Investing.com - Investing.com Nigeria
Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and BioNTech SE (BNTX) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Sanofi (SNY) and Johnson & Johnson (JNJ) - The Globe and Mail
NVO Rallies 11% in a Month: How Should Investors Play the Stock? - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Kuros Biosciences (CSBTF) - The Globe and Mail
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now? - TradingView
If You Invested $1,000 in Structure Therapeutics Inc ADR (GPCR) - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN) - The Globe and Mail
GPCRStructure Therapeutics Inc ADR Options - Finviz
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock? - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Strategy (MSTR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - TradingView
Form 4 Structure Therapeutics Inc ADR For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
(GPCR) Risk Channels and Responsive Allocation - Stock Traders Daily
Structure Therapeutics, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:GPCR) - TradingView
Form 144 Structure Therapeutics Inc. For: 25 June By Investing.com - Investing.com South Africa
[144] Structure Therapeutics Inc. SEC Filing - Stock Titan
Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Analysts Conflicted on These Healthcare Names: Phreesia (PHR) and Novo Nordisk (NVO) - The Globe and Mail
Shareholders Approve Directors, Auditors at 2026 Meeting - The Globe and Mail
Director at Structure Therapeutics (NASDAQ: GPCR) gets 39,453 options - Stock Titan
Structure Therapeutics (GPCR) director receives 39,453 share options at $15 - Stock Titan
Structure Therapeutics (GPCR) grants 39,453-share option award to director - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) reports 2026 shareholder voting outcomes - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Structure Therapeutics Inc Adr 주식 (GPCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jun 25 '26 |
Option Exercise |
0.34 |
23,634 |
8,036 |
252,594 |
2.44%
0.02%
자본화:
|
볼륨(24시간):